Three Building Products stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Top Insurance Stocks To Watch For 2015: Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc., formerly Pro-Pharmaceuticals, Inc., incorporated on January 26, 2001, is a development-stage company. The Company is engaged in drug development to create therapies for cancer and fibrotic disease. As of December 31, 2011, the Company has two compounds in development, one is to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from different natural starting materials, both possessing the property, which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, the Company's product candidate for cancer therapy, is a linear polysaccharide polymer consisted of mannose and galactose that has a defined chemical structure and is derived from a plant source. GR-MD-02, the Company's product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source.
GM-CT-01 has in development for the therapy of colorectal cancer and is in a Phase I/II clinical trial as a combination therapy with a tumor vaccine in patients with advanced melanoma. Based on the completed Phase I and partially completed Phase II clinical trials, the Company is exploring two additional potential indicia for the use of GM-CT-01 in combination with cancer chemotherapy. There are two additional pathways for the development of GM-CT-01 for use in treatment of cancer. GM-CT-01 was found to be generally safe when studied in a Phase I clinical trial in end-stage cancer patients with multiple tumor types alone and in combination with 5-Fluorouracil (5-FU), which is an Food and Drug Administration (FDA)-approved chemotherapy used for treatment of various types of cancer.
Advisors' Opinion:- [By Roberto Pedone]
Galectin Therapeutics (GALT) offers drug research and development to create new therapies for fibrotic disease and cancer. This stock closed up 9.6% to $12.06 in Monday's trading session.
Monday's Volume: 674,000
Three-Month Average Volume: 222,171
Volume % Change: 149%Shares of GALT jumped higher on Monday after Ascendiant initiated coverage on the stock with a buy recommendation.
From a technical perspective, GALT spiked sharply higher here with strong upside volume. This stock has been uptrending for the last three months, with shares ripping higher from its low of $3.95 to its recent high of $13.21. During that move, shares of GALT have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GALT within range of triggering a near-term breakout trade. That trade will hit if GALT manages to take out Monday's high of $12.44 and then once it clears its 52-week high at $13.21 with high volume.
Traders should now look for long-biased trades in GALT as long as it's trending above some near-term support levels at $11 or at $10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 222,171 shares. If that breakout hits soon, then GALT will set up to enter new 52-week-high territory above $13.21, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $16.
Hot Building Product Companies To Invest In Right Now: Hutchinson Technology Inc (HTCH)
Hutchinson Technology Incorporated (HTI), incorporated on October 29, 1965, is a global technology manufacturer. The Company is a supplier of suspension assemblies for hard disk drives. The Company operates in two segments: the Disk Drive Components Division and the BioMeasurement Division. The Company manufactures suspension assemblies for all sizes and types of hard disk drives. Suspension assemblies are components of disk drives that hold the read/write heads in position above the spinning magnetic disks.
The Company categorize its products as either suspension assemblies or other revenue, which consists primarily of revenue outside of the disk drive industry for precision component manufacturing, tool design, tool build and metrology, suspension assembly components, reimbursement for disk drive industry-related engineering services and specific disk drive program capacity and biomeasurement products. During the year ended September 29, 2013, the Company shipped 404 million suspension assemblies of all types, supplying all manufacturers of disk drives and head-gimbal assemblers.
The Company competes with Nihon Hatsujo Kabusikigaisha, Magnecomp Precision Technology Public Company Limited, NAT Peripheral (H.K.) Co., Ltd., Nitto Denko Corporation and Dai Nippon Corporation.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 electronic component player that's starting to move within range of triggering a big breakout trade is Hutchinson Technology (HTCH), which is a technology manufacturer that creates value by developing solutions to critical customer problems. This stock has been on fire during 2013, with shares up a whopping 75%.
If you take a look at the chart for Hutchinson Technology, you'll notice that this stock has been finding significant buying interest over the last two months, whenever it has pulled back to around $3.30 to $3.20 a share. This pattern could be signaling that shares of HTCH are forming a major bottoming chart pattern if those levels can hold as support. Shares of HTCH are now starting to flirt with its 50-day moving average at $3.56 a share. That move is starting to push the stock within range of triggering a big breakout trade above a key downtrend line.
Market players should now look for long-biased trades in HTCH if it manages to break out above its 200-day moving average of $3.65 a share and then once it clears more overhead resistance levels at $3.89 to $4.13 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 392,134 shares. If that breakout triggers soon, then HTCH will set up to re-test or possibly take out its next major overhead resistance levels at $4.75 to $5.50 a share, or even $6 a share.
Traders can look to buy HTCH off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.37 or at $3.17 a share. One can also buy HTCH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Hot Building Product Companies To Invest In Right Now: Emeritus Corporation (ESC)
Emeritus Corporation operates senior living communities in the United States. The company�s communities offer Alzheimer�s and dementia care, independent living, assisted living, specialized memory care, and skilled nursing care services. It also provides management services to independent and related-party owners of assisted living communities. As of November 15, 2012, the company operated approximately 470 senior living communities in 44 states with a resident capacity for approximately 50,000 residents. Emeritus Corporation was founded in 1993 and is headquartered in Seattle, Washington.
Advisors' Opinion:- [By John Kell]
Brookdale Senior Living Inc.(BKD) has agreed to merge with Emeritus Corp.(ESC) in a deal that values the operator of long-term, assisted-living facilities at about $1.4 billion, as the companies look to form a national senior-living-solutions company. Emeritus surged 34% to $28.75 premarket.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Emeritus (NYSE: ESC ) , whose recent revenue and earnings are plotted below. - [By Lisa Levin]
Emeritus (NYSE: ESC) shares gained 3.20% to touch a new 52-week high of $33.18. Emeritus shares have jumped 31.71% over the past 52 weeks, while the S&P 500 index has gained 16.93% in the same period.
Hot Building Product Companies To Invest In Right Now: HHGregg Inc.(HGG)
hhgregg, Inc. operates as a specialty retailer of consumer electronics, home appliances, and related services. The company offers video products, such as flat panel televisions, blu-rays, and DVD players; appliances, including washers and dryers, refrigerators, cooking ranges, dishwashers, freezers, and air conditioners; and digital camcorders, digital cameras, gaming bundles, home theater receivers, mattresses, MP3 players, computers, personal navigation, tablets, speaker systems, and telephones. It also sells a suite of services, including third-party premium service plans, and third-party in-home service and repair of products, as well as delivery and installation, and in-home repair and maintenance. The company operates its stores under the name of hhgregg. As of February 08, 2012, it operated 208 stores in Alabama, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland, Mississippi, New Jersey, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Virginia. The company is headquartered in Indianapolis, Indiana.
Advisors' Opinion:- [By Jayson Derrick]
hhgregg (NYSE: HGG) pre-announced sales totals for the fourth quarter in which net sales fell to $538.3 million from $597.6 million in the same quarter last year and below the consensus estimate of $551 million. Net loss per share for the quarter is expected to be $0.25, well below the $0.31 per share profit the company earned a year ago. Analysts were expecting the company to earn a profit of $0.10 per share in the quarter. Finally, hhgregg estimates that its fourth quarter comparable store sales decreased 9.9 percent with consumer electronics decreasing 18.9 percent and the wireless category decreasing 22.6 percent for the quarter. Fourth quarter and full year earnings are expected to be released on May 20. Shares lost 9.53 percent, closing at $7.88.
- [By Sam Mattera]
AFP/Getty Images TVs stand out as one of the premiere, big-ticket items of Black Friday. Even Kohl's (KSS), a store known for its clothing (not electronics), will have a few in stock that day, in an attempt to lure in a few extra bargain hunters. With so many different stores running specials, and all the different models on sale, there are literally dozens of different Black Friday TVs to choose from. While there are plenty of great deals available, a few stand out as being particularly noteworthy. Head to Walmart for the All-Around Cheapest Flat-Screen TV Walmart (WMT) will be selling a 32-inch LED Funai for just $98, making it one of the very cheapest TVs on sale this year. Discriminating buyers, however, should likely stay away -- Funai isn't in the same league as Sony (SNE) or Panasonic (PCRFY) when it comes to picture quality, and this particular set is just 720p (in contrast to full-HD 1080p). If you've never heard of Funai, the company generally sells its TVs under the Sylvania and Magnavox brands, two budget names not exactly known for their quality. Nevertheless, $98 for a 32-inch LED is hard (perhaps impossible) to beat. Shoppers looking for the cheapest flat-screen they can get their hands on should plan to be at Walmart Thanksgiving night. For a Great Deal on a Quality Samsung, Hit h.h. gregg At h.h. gregg (HGG), they'll also be offering a 32-inch LED, but unlike Walmart's Funai deal, this is on a model known for its quality. The set, Samsung's UN32EH5300, was declared one of the best 32-inch LCD TVs you can buy by LCD TV Buying Guide for 2012. It sports full-HD 1080p, and comes equipped with Samsung's smart TV suite -- owners can access digital content from sites like Netflix (NFLX) and Youtube. h.h. gregg will sell the TV for $299.99, what it claims is a 33 percent discount. Right now, Amazon (AMZN) is charging about $330 for the TV as part of its "Countdown to Black Friday" sale, making the h.h. gregg discount closer to 10 percent. (O
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, home-appliances and electronics retailer hhgregg (NYSE: HGG ) has received a distressing two-star ranking.
Hot Building Product Companies To Invest In Right Now: Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�� two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.
Supernus�� Late-Stage Neurology Portfolio
SPN-538 is an oral once-daily extended release topiramate product for the treatment of epilepsy. Topiramate is marketed by Johnson & Johnson under the brand name Topamax and is available in a generic form. As of December 31, 2009, Topiramate was available only in immediate release form and is indicated for monotherapy and adjunctive therapy of epilepsy and for the treatment of migraine. It works by enhancing the inhibitory effect of the Gamma-Aminobutyric Acid (GABA) neurotransmitter that regulates neuronal excitability throughout the nervous system, blocking the excitatory effect of the glutamate neurotransmitter, blocking the sodium channel and inhibiting the carbonic anhydrase enzyme.
Epliga is an oral once-daily extended release formulation of oxcarbazepine. As of December 31, 2009, Epliga was in Phase III trials. Oxcarbazepine is marketed by Novartis under the brand name Trileptal and is available in a generic form. Trileptal is indicated for monotherap! y and adjunctive therapy of epilepsy. Oxcarbazepine is an active voltage-dependent sodium channel blocker.
Supernus�� Psychiatry Portfolio
SPN-810 (molindone hydrochloride) is a treatment for impulsive aggression in patients with ADHD. As of December 31, 2009, it was in Phase II. SPN-810 is based on molindone hydrochloride. As of December 31, 2009, the Company had completed four clinical trials for SPN-810, including a Phase IIa trial, in which it tested the safety and tolerability of immediate release molindone hydrochloride in children with ADHD who suffer from serious persistent conduct problems. This open-label, dose-ranging trial randomized 78 children, 6-12 years of age, into one of four treatment groups, which were given four different doses of immediate release molindone hydrochloride, between 10 milligram and 40 milligram per day, depending on weight, three times a day over a six-week treatment period, after 2-5 weeks of titration. SPN-810 was well tolerated in the trial with no clinically meaningful changes in standard hematology, clinical chemistry values, vital signs or electrocardiogram results. SPN-810 also showed improvements on the primary and secondary outcome measures, such as conduct problem and ADHD scales, across all four treatment groups. SPN-812 is a non-stimulant treatment for ADHD. As of December 31, 2009, SPN-812 was in Phase II. SPN-812 is a selective norepinephrine reuptake inhibitor.
Supernus�� Technology Platforms
The Company has a long track record of developing products by applying technologies to known drugs to improve existing therapies and to enable the treatment of new indications. Supernus�� main technology platforms include: Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The Company�� technologies have been used in the approved and marketed products, including Carbatrol (carbamazepine), Equetro (carbamazepine), Adderall XR (mixe! d ampheta! mine salts), Sanctura XR (trospium chloride), Oracea (doxycycline) and Intuniv (guanfacine).
Advisors' Opinion:- [By Monica Gerson]
Supernus Pharmaceuticals (NASDAQ: SUPN) confirmed the FDA approval of its partner's heart blood-pressure treatment. Supernus shares jumped 18.24% to $8.75 in after-hours trading.
- [By Sara Sjolin]
Shares of Supernus Pharmaceuticals (SUPN) �could also be active, after the company jumped 20% after-hours on Monday after a drug on which the firm collaborated received Food and Drug Administration approval.
- [By Monica Gerson]
Supernus Pharmaceuticals (NASDAQ: SUPN) is expected to post a Q4 loss at $0.55 per share on revenue of $7.78 million.
Geron (NASDAQ: GERN) is projected to post a Q4 loss at $0.07 per share on revenue of $350.00 thousand.
Hot Building Product Companies To Invest In Right Now: Ashley(l)
Laura Ashley Holdings plc, together with its subsidiaries, engages in the design, manufacture, sourcing, distribution, sale, and licensing of clothing, accessories, and home furnishings in the United Kingdom and internationally. It offers various furniture products, including beds, upholstered furniture, mirrors, and cabinet furniture; home accessories, such as lighting products, gifts, bed linen, rugs, throws, cushions, and children?s accessories; and decorative products comprising curtains, blinds, fabrics, paints, decorative accessories, and wall coverings. The company also offers fashion products, such as clothing that include dresses, knitwear, tops, blouses, skirts, trousers, leggings, coats, jackets, swimwear, and shoes, as well as accessories comprising bags, purses, jewellery, and scarves. In addition, it provides design services for homes; and licenses various products, such as stationery, wooden flooring, blinds, interior window shutters, carpets, nursery produ cts, fireplaces, garden products, eyewear, tiles, promotional gifting, toiletries, shoes, and Fairtrade clothing. The company sells its products through retail stores, online, and mail order. As of January 29, 2011, it operated 217 stores, including 138 mixed product stores, 55 home stores, 22 home concession stores, 1 gifts and accessories store, and 1 clearance outlet in the United Kingdom; and 240 franchised stores in 29 countries. The company is based in London, the United Kingdom.
Advisors' Opinion:- [By Julius Ferraro]
Diamond offshore is a $9 billion dollar offshore driller that is currently 50.4% owned by Loews Corporation (L). I like that the Tisch family has a significant ownership because in the case of an economic downturn, Diamond Offshore can be provided with the capital that it may need by some of Loews other businesses. Its Expected to earn $4.80 for this year and trades at a fair valuation of 11.8 times earnings. In addition, out of all of the offshore drillers Diamond is the most conservative with $1.2 billion in cash and $1.5 billion in debt. Diamond Offshore is the only A rated drilling contractor.
- [By Robert Rapier]
Meanwhile, sponsor�Loews�(NYSE: L) has added to the cash drain by converting its class B units into common that will cost Boardwalk an additional $25 million in distributions annually. The Bluegrass Pipeline Boardwalk is marketing in a partnership with Williams (NYSE: WMB) is looking more and more as a defensive measure to replace lost business than as a path to future glory. And it now faces competition that could drive expected returns lower.
- [By Paul Ausick]
Big Earnings Movers: Petroleo Brasileiro SA (NYSE: PBR) is up 9.1% at $17.35 after reporting earnings and getting a ratings boost. Merck & Co. Inc. (NYSE: MRK) is down 2.5% at $45.39 as the company struggles to boost revenues. Burger King Worldwide Inc. (NYSE: BKW) is up 5.8% at $20.91 as franchise revenues rose much faster than costs. Loews Corp. (NYSE: L) is down 0.2% at $48.70.
- [By Ben Levisohn]
Looking for the next Berkshire Hathaway (BRK-B)? You could do worse than Loew’s Corp. (L), Deutsche Bank says.
Agence France-Presse/Getty ImagesBoth companies own insurance companies. And both use the cash spun off by those operations to invest elsewhere. Deutsche Bank dubs them “investor insurers,” and right now Loew’s looks cheap, the German investment bank’s analysts argue in a report starting Loew’s as a buy.
No comments:
Post a Comment